

Abbildungsnachweis

- L106 Henriette Rintelen, Velbert
L231 Stefan Dangl, München
O523 Anneli Nau, München
- Abb. 2.1 With kind permission from Springer Science+Business Media: Nervenarzt, MS-Register in Deutschland – Design und erste Ergebnisse der Pilotphase, 76, 2005, 967–75, P. Flachenecker et al., fig. 3
- Abb. 12.4 M. Sailer et al., Quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination, *Neurology*, 52, 3, 599–606
- Abb. 13.6 Volker Milnik, Düren
- Abb. 16.1 Multiple Sklerose Therapie Konsensusgruppe (MSTKG): Immunmodulatorische Stufentherapie der Multiplen Sklerose - Aktuelle Therapieempfehlungen (Stand September 2006); Hrsg. DMSG, Bundesverband e.V.
- Abb. 16.3 With kind permission from Springer Science+Business Media: Beta-Interferon. Schwerpunkt Multiple Sklerose, 2000, Hans-Joachim Obert, Dieter Pöhlau, fig. 1
- Abb. 16.5 The IFNB Multiple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis Group, Interferon beta-1b in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial, *Neurology*, 45, 7, 1277–1285
- Abb. 16.6 L. D. Jacobs et al., *Ann Neurol* 1996;39:285–294, John Wiley and Sons
- Abb. 16.9, 16.18–16.20 Novartis Pharma, Nürnberg
- Abb. 16.10 M. Clanet et al., A randomized, double-blind, dose-comparison study of weekly interferon β -1a in relapsing MS, *Neurology*, 59, 10, 1507–1517
- Abb. 16.16 Haas J. High dose IVIG in the post partum period for prevention of exacerbations in MS. *Multiple Sclerosis*, MacMillan Publishers Ltd. 2000;6, Suppl 2: 18–20
- Abb. 16.21 The Lancet, 338, Yudkin et al., Overview of azathioprine treatment in multiple sclerosis, 1051–1055, 1991
- Abb. 17.1 Current pharmaceutical design, 2003, Bentham Science Publishers Ltd.